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Pneumonia
• Community acquired pneumonia (CAP)
• Healthcare associated pneumonia (HCAP)
• Hospital-acquired pneumonia (HAP)
• Ventilator associated pneumonia (VAP)
• Aspiration pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
TJUH Antimicrobial Guidelines
• Confluence
– https://confluence.jefferson.edu/
– Antimicrobial Stewardship
Community Acquired Pneumonia 
(CAP)
• Occurs within 48 hours of hospital admission
• Severe CAP
– Patients with 1 major or ≥3 minor criteria
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
Community Acquired Pneumonia 
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
Routine Diagnostic Work-up
• History and Physical Exam
• Vital signs
• Pulse oximetry and/or ABG
• Chest x-ray (PA and lateral)
• CBC with differential
• Basic metabolic panel
• Sputum and blood cultures
• Procalcitonin is not recommended in adults with clinically 
suspected and radiographically confirmed pneumonia
• Other diagnostics may be required in the appropriate 
clinical setting (travelers, immunocompromised patients, 
HIV infection, etc.)
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
Additional Considerations
Community Acquired Pneumonia
• Assess risk factors for community acquired MRSA 
(ca-MRSA):
– Recent hospitalization and IV antibiotics within the 
last 90 days
– Preceding or concurrent influenza like illness
– CAP requiring ICU admission
– Necrotizing or cavitary infiltrates
– Empyema
– Previous colonization or infection with MRSA
– Intravenous drug abuse
– Immunocompromised patients
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
Community Acquired Pneumonia
• Assess risk factors for Pseudomonas aeruginosa
– Recent hospitalization AND IV antibiotic use within the 
past 90 days
– Immunocompromised patients
– Structural lung disease (CF, bronchiectasis)
– Hospitalization for ≥2 days within 90 days
– Residence in a nursing home or extended care facility
– Home infusion therapy (including antibiotics)
– Home wound care
– Family member with multidrug-resistant organisms 
(MDRO)
– Chronic hemodialysis (HD) within 30 days
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
CAP Treatment Algorithm
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
CAP Treatment Algorithm
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
Community Acquired Pneumonia
• Which antimicrobial regimen would you select 
for a non-ICU pt suspected to have non-severe 
CAP?
– A. Vancomycin and Cefepime
– B. Meropenem
– C. Ceftriaxone and Azithromycin
– D. I order what Shirley tells me to
CAP De-escalation of Therapy
• De-escalation of therapy 
– Based on clinical improvement and culture results
– For non critically ill patients, transition to oral therapy 
as soon as possible
– Pts initially treated with ceftriaxone + azithromycin:
• Cefuroxime 500 mg po q12hr* +/- azithromycin 500 mg po 
q24hr
– Pts initially treated with levofloxacin or PCN allergic:
• Levofloxacin 750 mg po daily*
*requires renal dosing
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
CAP Duration of Therapy
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
CAP Therapy Discontinuation
• Discontinue abx if:
– Afebrile for 48-72 hrs AND has no more than 1 of the 
following:
• HR > 100 beats/min
• RR > 24 breaths/min
• BP < 90 mm Hg
• O2 sat < 90%
• Altered mental status
– Cough and CXR abnormalities can take several weeks 
to improve
• No need to extend duration if clinically well
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia

Fluoroquinolone (FQ) Safety
• FDA warnings and precautions
– Increased risk of tendonitis and tendon rupture
– Risk of worsening symptoms for those with 
myasthenia gravis
– Potential for irreversible peripheral neuropathy
– Increase in mental health adverse effects and 
blood glucose disturbances
– Increased risk of aneurysm and dissection
– C.difficile
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020634s070lbl.pdf#page=52
Hospital-Acquired Pneumonia (HAP)
• Pneumonia that occurs ≥ 48 hours after 
admission 
• Not incubating at the time of admission
• Also referred to as nosocomial pneumonia
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
HAP Suspected Organisms
*HAP and VAP may be caused by a wide variety of pathogens, can be polymicrobial, and depends in 
large part upon whether the patient has risk factors for MDR pathogens. Differences in patient 
factors and the hospital flora also influence the patterns of pathogens seen.
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
HAP Treatment Algorithm
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Metlay JP, et al.Am J Respir Crit Care Med.2019;200(7):e45-e67 
HAP Treatment Algorithm
• Double coverage for gram-negative organisms
– Patients who have received prior intravenous 
antibiotics within the preceding 90 days
– Structural lung disease (ie. bronchiectasis, CF) 
• At risk for multidrug-resistant (MDR) gram-
negative pathogens, including pseudomonas,  
should receive 2 different agents with gram-
negative activity
Additional Considerations
HAP De-escalation of Therapy
• Deescalate based on clinical improvement and 
culture results.
– For non-critically ill patients, transition to oral therapy 
as soon as possible.
• Culture–negative step down therapy:
– Obtain MRSA nasal swab upon admission. 
– If no MRSA isolated and nasal screen negative, 
consider discontinuation of vancomycin after 48hrs
• If no culture data available and the patient is 
improving, you can deescalate to levofloxacin 
750mg PO q24h
HAP Duration of Therapy
• 7 days!
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
HAP Therapy Discontinuation
• Discontinue antibiotics if:
– Patient is afebrile for 48-72hours AND has no more 
than 1 of the following:
• HR >100 beats/min
• RR >24 breaths/min
• BP < 90mmg Hg
• O2 Sat < 90%
• Altered Mental Status
– Cough and CXR abnormalities can take several weeks 
to improve
• No need to extend duration if clinically well
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
MRSA Nasal Screen
Chan JD, Dellit TH, Choudhuri JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus 
aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. Crit Care Med. 
2012;40(5):1437-1442. doi:10.1097/CCM.0b013e318243168e
MRSA Nasal Screen
• Prospective observational study conducted at 
a university-affiliated urban teaching hospital
• VAP patients ≥ 16 years old
– 924 episodes of suspected VAP evaluated with 
bronchoscopy
– 393 pts had microbiologically confirmed VAP
• 5 excluded due to <16 yrs or screen not performed
– 54 patients were colonized with MRSA by ASC
• Common sites: nares, posterior oropharynx, trachea
Chan JD, Dellit TH, Choudhuri JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus 
aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. Crit Care Med. 
2012;40(5):1437-1442. doi:10.1097/CCM.0b013e318243168e
MRSA Nasal Screen
• Sensitivity 70.3% (95% CI, 52.8-83.6)
• Specificity 92% (95% CI, 88.5-94.5)
• Positive predictive value 48.1% (95% CI, 34.5-
62)
• Negative predictive value 96.7% (95% CI, 94-
98.3)
Chan JD, Dellit TH, Choudhuri JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus 
aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. Crit Care Med. 
2012;40(5):1437-1442. doi:10.1097/CCM.0b013e318243168e
MRSA Nasal Screen
• High negative predictive value 
– Indicates that negative screens are very accurate 
for excluding MRSA as a cause of pneumonia
Aspiration Pneumonia
• Aspiration – inhalation of oropharyngeal or 
gastric contents into larynx and lower 
respiratory tract
– Contents may include:
• Different substances (blood, vomitus, food particles)
• Oropharyngeal secretions
• Microbiological flora
Waybright, RA et al. Treatment of clinical aspiration: A reappraisal. Am J Health-
Syst Pharm – Vol 70 Aug 1 2013; 1291-1300.
Aspiration Pneumonia
• Complications of aspiration:
– Chemical pneumonitis 
• Damage of lung parenchyma after inhalation of sterile 
stomach or oropharyngeal contents into lower airway
– Due to gastric acid and delayed inflammatory reaction
• Non-infectious process
– Aspiration pneumonia
• Infectious process
• Occurs after inhalation of colonized pathogenic bacteria into 
lower airway from oropharyngeal area or colonized gastric 
contents
• Often occurs silently
Waybright, RA et al. Treatment of clinical aspiration: A reappraisal. Am J Health-
Syst Pharm – Vol 70 Aug 1 2013; 1291-1300.
Aspiration Pneumonia
• Despite distinct physiological processes, 
clinical presentation can be difficult to 
distinguish
• Bacteriology
– Associated microbial spectrum included gram 
positive (S. aureus, S. pneumoniae), gram negative 
(H. influenzae, enterobacteriaceae), and 
anaerobes (bacteroides, peptostreptococcus, 
fusobacterium)
– From studies from the 1970s
Waybright, RA et al. Treatment of clinical aspiration: A reappraisal. Am J Health-
Syst Pharm – Vol 70 Aug 1 2013; 1291-1300.
Aspiration Pneumonia
• Broader spectrum antibiotics not necessarily 
more effective
• Potential abx choice should target 
nonresistant gram positive (Staphylococcus
and Streptococcus species) and gram negative 
(Enterobacteriaceae, H. influenzae)
Aspiration Pneumonia
• Pneumonia (fever, cough, infiltrate) that 
develops 48 – 72 hrs after suspected or 
witnessed aspiration event
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Question
• In aspiration pneumonia, should you cover for 
anaerobes?
– Yes
– No
Aspiration Pneumonia
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Aspiration Pneumonia
• Assess for risk factors for anaerobic infection:
– Loss of consciousness due to alcoholism
– Seizures
– Gingival disease
– Esophageal motility issues
– Lung abscess
– Empyema
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Aspiration Pneumonia
• De-escalation of therapy
– Culture negative step down therapy:
• Amoxicillin/clavulanate (Augmentin) 875 mg po q12hr
OR
• Levofloxacin 750 mg po q24hr +/- metronidazole
OR
• Cefuroxime 500 mg po q12hr (if anaerobic coverage not 
required)
• Reassess patients in 48-72 hrs, if no symptoms or 
confirmatory cx or imaging, likely chemical 
pneumonitis and can discontinue abx
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Antimicrobial Dosing
https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia
Wrap-up
• De-escalate when appropriate
– Prolonged use of broad spectrum abx can lead to:
• Resistance
• C. diff infections
• Longer duration does not equal better 
outcomes!
Questions?
